Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

Therapeutic Drug Monitoring

Volumn 22, Issue 2, 2000, Pages 143-154

  Rasmussen, Birgitte Buur ^a   Brøsen, Kim ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b NONE

Author keywords

Drag interactions; Selective serotonin reuptake inhibitors; Therapeutic drag monitoring

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 3A; DEBRISOQUINE 4 HYDROXYLASE; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; LEVOMEPROMAZINE; PAROXETINE; PERPHENAZINE; PROPAFENONE; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERFENADINE; THIORIDAZINE;

BIOTRANSFORMATION; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; ENZYME SPECIFICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; STEREOCHEMISTRY; TREATMENT OUTCOME;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 0034075099     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200004000-00001     Document Type: Review

References (121)

1. Gram LF, Kragh Sorensen P, Kristensen CB, Moller M, Pedersen OL, Thayssen P. Plasma level monitoring of antidepressants: theoretical basis and clinical application. Adv Biochem Psychopharmacol 1984;39:399-411.
2. Shimada T, Yamazaki H, Mimura M, Inui Y, uengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
3. Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996;18:393-396.
4. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 1989;86:7696-7700.
5. Robson RA, Matthews AP, Miners JO, et al. Characterisation of theophylline metabolism in human liver microsomes. Br J Clin Pharmacol 1987;24:293-300.
6. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamme is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-1214.
7. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S- mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-15422.
8. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-187.
9. Zanger UM, Vilbois F, Hardwick JP, Meyer UA. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 1988;27:5447-5454.
10. Brøsen K, Gram LF. Clinical significance of the sparteine/ debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989;36:537-547.
11. Brøsen K. Isozyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nord J Psychiatry Suppl 1993; 30:21-26.
12. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 1993;71:1002-1009.
13. Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991;11: 224-225.
14. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994;27:175-190.
15. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-220.
16. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-160.
17. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280:927-933.
18. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997;7:1-10.
19. Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15:18-24.
20. Sindrup SH; Brøsen K, Hansen MG, Aaes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-17.
21. Wong DT, Fuller RW, Robertson DW. Fluoxetine and its two enantiomers as selective serotonin uptake inhibitors. Acta Pharm Nord 1990;2:171-180.
22. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, LeBel M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996;60: 512-521.
23. Fjordside L, Jeppesen U, Eap CB, Powell K, Baumann P, Brøsen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolisers of sparteine. Pharmacogenetics 1999;9: 55-60.
24. Fuller RW, Snoddy HD, Krushinski JH, Robertson DW. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 1992;31:997-1000.
25. Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-287.
26. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992;33:521-523.
27. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-295.
28. De Vries MH, van Harten J, Van Bemmel P, Raghoebar M. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Dispos 1993;14: 291-296.
29. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995;58:399-403.
30. Carrillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-190.
31. Hartter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 1992;38:2082-2086.
32. Spigset O, Ohman R. A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics. J Clin Psychopharmacol 1996;16:254-255.
33. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32S1:1-21.
34. Eap CB, Baumann P. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. J Chromatogr 1996; 686:51-63.
35. Olesen OV, Linnet K. Simplified high-performance liquid chromatographic method for the determination of citalopram and desmethylcitalopram in serum without interference from commonly used psychotropic drugs and their metabolites. J Chromatogr B Biomed Appl 1996;675:83-88.
36. Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1995;17:273-279.
37. Rochat B, Amey M, Van GH, Testa B, Baumann P. Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 1995;7:389-395.
38. Foglia JP, Pollock BG, Kirshner MA, Rosen J, Sweet R, Mulsant B. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 1997;33:109-112.
39. Haupt D. Determination of citalopram enantiomers in human plasma by liquid chromatographic separation on a Chiral-AGP column. J Chromatogr B Biomed Appl 1996;685:299-305.
40. Fontanille P, Jourdil N, Villier C, Bessard G. Direct analysis of fluoxetine and norfluoxetine in plasma by gas chromatography with nitrogen-phosphorus detection. J Chromatogr B Biomed Sci Appl 1997;692:337-343.
41. Crifasi JA, Le NX, Long C. Simultaneous identification and quantitation of fluoxetine and its metabolite, norfluoxetine, in biological samples by GC-MS. J Anal Toxicol 1997;21:415-419.
42. Clausing P, Rushing LG, Newport GD, Bowyer JF. Determination of D-fenfluramine, D-norfenfluramine and fluoxetine in plasma, brain tissue and brain microdialysate using high-performance liquid chromatography after precolumn derivatization with dansyl chloride. J Chromatogr B Biomed Sci Appl 1997; 692:419-426.
43. Misztal G, Hopkala H. Determination of fluoxetine in human plasma using reserved phase HPLC. Pharmazie 1997;52:854-856.
44. Holladay JW, Dewey MJ, Yoo SD. Quantification of fluoxetine and norfluoxetine serum levels by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997;704:259-263.
45. Eap CB, Gaillard N, Powell K, Baumann P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1996;682:265-272.
46. Potts BD, Parli PJ. Analysis of the enantiomers of fluoxetine and norfluoxetine in plasma and tissue using chiral derivatization and normal-phase liquid chromatography. J Liquid Chromatogr 1992; 15:665-681.
47. Peyton AL, Carpenter R, Rutkowski K. The stereospecific determination of fluoxetine and norfluoxetine enantiomers in human plasma by high-pressure liquid chromatography (HPLC) with fluorescence detection. Pharm Res 1991;8:1528-1532.
48. Foglia JP, Sorisio D, Kirshner M, Pollock BG. Quantitative determination of paroxetine in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Appl 1997;693:147-151.
49. Hartter S, Hermes B, Szegedi A, Hiemke C. Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography. Ther Drug Monit 1994;16:400-406.
50. Gupta RN, Dziurdzy SA. Therapeutic monitoring of sertraline. Clin Chem 1994;40:498-499.
51. Rogowsky D, Marr M, Long G, Moore C. Determination of sertraline and desmethylsertraline in human serum using copolymeric bonded-phase extraction, liquid chromatography and gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1994;655:138-141.
52. Patel J, Spencer EP, Flanagan RJ. HPLC of sertraline and norsertraline in plasma or serum. Biomed Chromatogr 1996;10:351-354.
53. Logan BK, Friel PN, Case GA. Analysis of sertraline (Zoloft) and its major metabolite in postmortem specimens by gas and liquid chromatography. J Anal Toxicol 1994;18:139-142.
54. Dufour H, Bouchacourt M, Thermoz P, et al. Citalopram - a highly selective 5-HT uptake inhibitor - in the treatment of depressed patients. Int Clin Psychopharmacol 1987;2:225-237.
55. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-469.
56. Bjerkenstedt L, Flyckt L, Overo KF, Lingjaerde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985;28:553-557.
57. Benazzi F. A "therapeutic window" with citalopram in a case of depression. Pharmacopsychiatry 1996;29:42
58. Kelly MW, Perry PJ, Holstad SG, Garvey MJ. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 1989;11:165-170.
59. Torok BG, Baker GB, Coutts RT, McKenna KF, Aspeslet LJ. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection. J Chromatogr 1992;579:99-106.
60. Beasley-CM J, Bosomworth JC, Wernicke JF. Fluoxetine: relationships among dose, response, adverse events and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990;26:18-24.
61. Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 1993;8:25-29.
62. Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand 1989; 79:586-596.
63. Goodnick PJ. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharmacol Bull 1991;27:503-512.
64. Cain JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? J Clin Psychiatry 1992;53:272-277.
65. Montgomery SA, Baldwin D, Shah A, Green M, Fineberg N, Montgomery D. Plasma-level response relationships with fluoxetine and zimelidine. Clin Neuropharmacol 1990;13 S1:S71-S75
66. Fichtner CG, Jobe TH, Braun BG. Possible therapeutic window for serotonin reuptake inhibitors. J Clin Psychiatry 1994;55:36-38.
67. Tyrer SP, Marshall EF, Griffiths HW. The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes, and whole blood 5HT. Biol Psychiatry 1990; 14:797-805.
68. Keck PE Jr., McElroy SL. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J Clin Psychiatry 1992;53:127-129.
69. Schwartz EM, Markovitz PJ. Fluoxetine responsivity mediated by serum levels, not dose. J Clin Psychopharmacol 1993;13:363-364.
70. Ceccherini NA, Guidi L. Fluoxetine: the relationship between response, adverse events, and plasma concentrations in the treatment of bulimia nervosa. Int Clin Psychopharmacol 1993;8:311-313.
71. Goff DC, Midha KK, Sand SO, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995;117:417-423.
72. Fava M, Rosenbaum JF, Cohen L, et al. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord 1992;25:229-234.
73. Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154:963-969.
74. De WJ, Mertens C, Wakelin JS. Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. Br J Clin Pharmacol 1983;15 S3:427S-431S.
75. De WJ, Doogan DP. Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 1982;4:249-259.
76. Kasper S, Dotsch M, Kick H, Vieira A, Moller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993;3:13-21.
77. Klok CJ, Brouwer GJ, van PH, Doogan D. Fluvoxamine and clomipramine in depressed patients. A double-blind clinical study. Acta Psychiatr Scand 1981;64:1-11.
78. Foglia JP, Perel JM, Nathan RS, and Pollock BG. Therapeutic drug monitoring of fluvoxamine, a selective antidepressant. Clin Chem 1990;36:1043.
79. Tasker TC, Kaye CM, Zussman BD, Link CG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989;350:152-155.
80. Laursen AL, Mikkelsen PL, Rasmussen S, le-Fevre HP. Paroxetine in the treatment of depression - a randomized comparison with amitriptyline. Acta Psychiatr Scand 1985;71:249-255.
81. Danish University Antidepressant Group. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disorders 1990;18:289-299.
82. Kuhs H, Schlake HP, Rolf LH, Rudolf GA. Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline. Acta Psychiatr Scand 1992;85:364-369.
83. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75.
84. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994;27:307-330.
85. Brøsen K, Rasmussen, BB. 1996) Selective serotonin reuptake inhibitors: Pharmacokinetics and drug interactions. In: Feighner JP and Boyer WF, eds. Selective serotonin reuptake inhibitors: Advances in basic research and clinical practice. 2nd ed. Chichester: John Wiley and Sons; 1996:87-108.
86. Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 1996;29:156-158.
87. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-261.
88. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265.
89. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-409.
90. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988;145:1478-1478.
91. Brøsen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br J Clin Pharmacol 1991;32:136-137.
92. Rasmussen BB, Nielsen TL, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur J Clin Pharmacol 1998;54:735-740.
93. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78.
94. Rasmussen BB, Mäenpää J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 1995;39:151-159.
95. von Moltke LL, Greenblatt DJ, Cotreau Bibbo MM, Haumatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake inhibitors, antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
96. Centorrino F, Baldessarini RJ, Kando J, et. al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151: 123-125.
97. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988;43: 412-419.
98. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-486.
99. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992;14:194-196.
100. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding. Eur J Clin Pharmacol 1991;40:119-120.
101. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993;15:243-246.
102. Nielsen KK, Flinois JP, Beaune P, Brøsen K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996;277:1659-1664.
103. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Safety 1991;6:460-462.
104. Diot P, Jonville AP, Gerard F, et al. Possible interaction between theophylline and fluvoxamine. Therapie 1991;46:170-171.
105. Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M. Interaction between fluvoxamine and theophylline. Pharmac J 1992;137
106. Puranik A, Fitzpatrick R, Ananthanarayanan TS. Monitor serum theophylline. Care of elderly 1993;237
107. van den Brekel A, Harrington L. Toxic effects of theophylline caused by fluvoxamine. Can Med Assoc J 1994;151:1289-1290.
108. Jerling M, Lindstrom L, Londesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-374.
109. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine J Clin Psychopharmacol 1994;14:279-281.
110. Jeppesen U, Loft S, Poulsen HE, Brøsen K. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-222.
111. Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo. Fundam Clin Pharmacol 1996;10: 156-157.
112. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalyzed biactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-286.
113. Brøsen K, Gram LF, Kragh Sørensen P. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Momit 1991;13:177-182.
114. Brøsen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-355.
115. Leinonen E, Koponen HJ, Lepola U. Paroxetine increases serum trimipramine concentration. Hum Psychopharmacol 1995;10: 345-347.
116. Skjelbo E, Brøsen K. [Interaction between paroxetine and clomipramine as a possible reason for admission to a department of internal medicine]. Ugeskr Laeger 1998;160(39):5665-5666.
117. Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism;comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997;43(6):619-626.
118. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-98.
119. Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry 1993; 150:1125-1126.
120. Barros J, Asnis G. An interaction of sertraline and desipramine. Am J Psychiatry 1993;150:1751.
121. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 1996;78:203-208.